KLOTHO NEUROSCIENCES INC (KLTO) Fundamental Analysis & Valuation

NASDAQ:KLTO • US49876K1034

Current stock price

0.5242 USD
+0 (+0.81%)
At close:
0.5339 USD
+0.01 (+1.85%)
After Hours:

This KLTO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KLTO Profitability Analysis

1.1 Basic Checks

  • In the past year KLTO has reported negative net income.
  • In the past year KLTO has reported a negative cash flow from operations.
KLTO Yearly Net Income VS EBIT VS OCF VS FCFKLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -112.08%, KLTO is doing worse than 78.96% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -113.73%, KLTO is in line with its industry, outperforming 42.08% of the companies in the same industry.
Industry RankSector Rank
ROA -112.08%
ROE -113.73%
ROIC N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KLTO Yearly ROA, ROE, ROICKLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KLTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLTO Yearly Profit, Operating, Gross MarginsKLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. KLTO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KLTO has more shares outstanding
  • KLTO has a worse debt/assets ratio than last year.
KLTO Yearly Shares OutstandingKLTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
KLTO Yearly Total Debt VS Total AssetsKLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • KLTO has an Altman-Z score of 154.34. This indicates that KLTO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 154.34, KLTO belongs to the top of the industry, outperforming 99.03% of the companies in the same industry.
  • There is no outstanding debt for KLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 154.34
ROIC/WACCN/A
WACCN/A
KLTO Yearly LT Debt VS Equity VS FCFKLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • KLTO has a Current Ratio of 83.68. This indicates that KLTO is financially healthy and has no problem in meeting its short term obligations.
  • KLTO has a Current ratio of 83.68. This is amongst the best in the industry. KLTO outperforms 100.00% of its industry peers.
  • A Quick Ratio of 83.68 indicates that KLTO has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 83.68, KLTO belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 83.68
Quick Ratio 83.68
KLTO Yearly Current Assets VS Current LiabilitesKLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. KLTO Growth Analysis

3.1 Past

  • KLTO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.42%.
EPS 1Y (TTM)-38.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. KLTO Valuation Analysis

4.1 Price/Earnings Ratio

  • KLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLTO Price Earnings VS Forward Price EarningsKLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLTO Per share dataKLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KLTO Dividend Analysis

5.1 Amount

  • KLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KLTO Fundamentals: All Metrics, Ratios and Statistics

KLOTHO NEUROSCIENCES INC

NASDAQ:KLTO (3/11/2026, 8:07:43 PM)

After market: 0.5339 +0.01 (+1.85%)

0.5242

+0 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-31
Inst Owners6.06%
Inst Owner Change145.53%
Ins Owners8.33%
Ins Owner Change54.3%
Market Cap38.55M
Revenue(TTM)N/A
Net Income(TTM)-11.29M
AnalystsN/A
Price TargetN/A
Short Float %3.35%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.13
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -112.08%
ROE -113.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 83.68
Quick Ratio 83.68
Altman-Z 154.34
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-412.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-412.45%
OCF growth 3YN/A
OCF growth 5YN/A

KLOTHO NEUROSCIENCES INC / KLTO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KLOTHO NEUROSCIENCES INC (KLTO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KLTO.


What is the valuation status for KLTO stock?

ChartMill assigns a valuation rating of 0 / 10 to KLOTHO NEUROSCIENCES INC (KLTO). This can be considered as Overvalued.


What is the profitability of KLTO stock?

KLOTHO NEUROSCIENCES INC (KLTO) has a profitability rating of 0 / 10.


What is the financial health of KLOTHO NEUROSCIENCES INC (KLTO) stock?

The financial health rating of KLOTHO NEUROSCIENCES INC (KLTO) is 8 / 10.